FDA Approves Johnson and Johnson’s IMAAVY for Warm Autoimmune Hemolytic Anemia | iPharmaCenter

The U.S. Food and Drug Administration has approved IMAAVY, also known as nipocalimab, for adults and children aged 12 years and older with warm autoimmune hemolytic anemia who are currently receiving or have previously received corticosteroids.

The decision gives patients with this rare and potentially life-threatening blood disorder the first treatment specifically approved for warm autoimmune hemolytic anemia. Johnson and Johnson said the approval followed the agency’s priority review process.

A Targeted Approach to wAIHA

Warm autoimmune hemolytic anemia develops when the immune system produces harmful immunoglobulin G antibodies that attach to and destroy red blood cells.

The resulting decline in red blood cells can cause severe anemia, persistent fatigue, reduced physical capacity, and serious health complications.

Historically, treatment has relied mainly on corticosteroids and other immune-suppressing medicines. These approaches can affect broad areas of immune function rather than directly addressing the antibodies responsible for red blood cell destruction.

IMAAVY is designed to block the neonatal Fc receptor, or FcRn. By interfering with this pathway, the medicine aims to lower disease-causing IgG autoantibodies while preserving important aspects of B-cell activity.

ENERGY Study Supported the Decision

The approval was based on findings from the Phase 2/3 ENERGY study, a randomized, double-blind, placebo-controlled trial involving adults with warm autoimmune hemolytic anemia.

The study’s primary measure was durable hemoglobin response. This endpoint assessed whether patients achieved a meaningful increase in hemoglobin that remained stable over time.

At 24 weeks, approximately three times as many patients receiving the approved regimen achieved a durable hemoglobin response compared with those given placebo. Available study results showed a durable response in 23.7% of patients who received 30 milligrams per kilogram intravenously every four weeks, compared with 7.7% of placebo recipients.

The treatment group also recorded an average hemoglobin increase of 1 gram per deciliter by the first week.

Fatigue Scores Also Improved

Patients treated with IMAAVY reported better fatigue outcomes at Week 24.

The mean FACIT-Fatigue score was 3.5 points higher than the score recorded in the placebo group. Higher scores on this measure indicate less fatigue.

For people living with warm autoimmune hemolytic anemia, this improvement may be relevant because low hemoglobin can substantially affect energy, daily activities, and overall quality of life.

The safety results from the ENERGY study were consistent with the known safety profile of IMAAVY in generalized myasthenia gravis.

Study Included Long-Term Follow-Up

ENERGY enrolled 115 adults who were randomly assigned to one of two nipocalimab dosing schedules or placebo.

Following 24 weeks of blinded treatment, participants could enter an open-label extension. Patients in that extension received nipocalimab for up to 144 weeks, followed by six weeks of monitoring after their final assessment.

The extended follow-up is intended to provide additional information on the durability of treatment response and long-term safety.

Significance for Patients

The approval introduces a treatment designed to reduce the specific IgG autoantibodies that drive warm autoimmune hemolytic anemia.

For patients who have received corticosteroids, IMAAVY offers a new option in a condition where treatment choices have historically been limited and often relied on broad immune suppression.

The therapy is approved for patients aged 12 years and older who are currently or previously treated with corticosteroids. Its use should be determined by a qualified healthcare professional based on the patient’s medical history, disease severity, and treatment response.